Dupixent

About Dupixent

• Dupixent/dupilumab is a biologic medication commonly used to treat eczema, asthma, and six other chronic inflammatory conditions, but concerns about the drug have emerged. 
• Recent studies have shown a connection between the use of Dupixent and an increased risk of cutaneous T-cell lymphoma (CTCL). Patients have suffered widespread effects, including costly medical bills, emotional distress, and a decreased quality of life.
• Individuals who developed CTCL after using Dupixent should consult with a dangerous drug attorney to discuss their legal options to seek compensation and accountability.

Why Hire CSS for Your Dupixent Lawsuit

Pharmaceutical companies have a responsibility to ensure the medications they design and manufacture are safe. They must adequately warn medical providers and patients of the risks and possible side effects of their medications and provide proper instructions for use. Unfortunately, as dangerous drug attorneys, we know this doesn’t always happen, and now, manufacturers of Dupixent, also known as dupilumab, are facing growing litigation.

The attorneys at Childers, Schlueter & Smith filed the first Dupixent lymphoma lawsuit in Georgia. Many others have been filed across the US, and the first wrongful death case emerged in late 2025.

Through our extensive experience with dangerous drug lawsuits, we’re confident there is strong evidence for these cases because of research linking dupilumab to CTCL. Studies have shown that individuals who took Dupixent face up to a four-and-a-half times increased relative risk of developing cutaneous T-cell lymphoma. The evidence is significant, and the medication’s manufacturers, Sanofi and Regeneron, knew or should have known of the risks but failed to warn patients and doctors.

Our firm has spent decades protecting the rights of individuals harmed by dangerous and defective drugs. If you were diagnosed with CTCL and used Dupixent, contact us for a free consultation.

Research Linking Dupixent to Increased Risk of CTCL

After approval by the FDA in 2017, reports of CTCL diagnoses among patients who were treated with Dupixent/dupilumab for asthma and eczema began coming in. The reports prompted multiple research teams to examine whether there’s a link between the drug and a rare type of lymphoma, with several results released in the past two years.

One study considered as crucial evidence in dangerous drug lawsuits against Dupixent manufacturers was published in August 2024. It included nearly 20,000 patients who used the medication, and concluded there’s an increased risk of cutaneous T-cell lymphoma after dupilumab use for atopic dermatitis (eczema).

More specifically, the study found:

• Patients who took Dupixent had a 4.59 increased relative risk of developing CTCL compared to those who didn’t.
• The risk was highest in the first year of therapy; 62% of patients with CTCL were diagnosed within the first year.
• About half of the patients diagnosed with the cancer were over the age of 60.

Other studies have reached similar conclusions, that there’s a connection between Dupixent and cutaneous T-cell lymphoma; the numbers vary, with increased relative risks of the rare lymphoma ranging between three to four and a half times higher than in patients who didn’t take the medication.

Overall, study findings have further raised concerns among doctors and industry advocates. In general, researchers largely agree that more examination is needed to fully understand the risks and how Dupixent may mask or unmask CTCL in asthma and eczema patients.

Dupixent Lymphoma Lawsuits in Georgia and the U.S.

The Dupixent CTCL lawsuits are in early stages. Our dangerous drug attorneys are continuing to consult with individuals who took Dupixent and were later diagnosed with CTCL. We expect more people to come forward in the coming months as awareness of the connection between T-cell lymphoma and Dupixent grows.

Dupixent lymphoma lawsuits allege that Regeneron and Sanofi, manufacturers of Dupixent, failed to update the warning label after studies linked the medication to an increased risk of CTCL. Many plaintiffs also claim that the lack of warning resulted in a delayed diagnosis, allowing the cancer to progress further and require more intense treatment that could have been avoided if it had been caught earlier.

The impact of a dangerous or defective drug can have both immediate and long-term effects on the patient and their families. For individuals who developed CTCL and took Dupixent, they’ve had to undergo a range of expensive medical treatments, leading to high medical costs that have placed a financial burden on them and their families. But the impact of a lymphoma diagnosis extends far beyond the cost of medical bills; emotional distress, time off work, and diminished quality of life are damages being sought in Dupixent CTCL lawsuits.

Like many dangerous drug cases, Dupixent lawsuits could end up being consolidated into multidistrict litigation (MDL). This occurs when numerous plaintiffs allege they suffered similar injuries and present similar evidence, which is what happened with the Depo-Provera brain tumor lawsuits. MDL is meant to streamline the legal process and often leads to settlement agreements before cases go to trial; once both the defendants and plaintiffs see the evidence, arguments, and possible outcome of cases, drug manufacturers are often eager to settle to avoid years of legal battles for individual lawsuits.

At Childers, Schlueter & Smith, our attorneys are here to help if you took Dupixent and were diagnosed with CTCL. Since we’ve handled numerous other mass torts involving dangerous pharmaceuticals, we have the experience needed to navigate the complex legal nuances and medical implications of dupilumab lymphoma lawsuits.

What Is Dupixent?

Dupixent, also known by its generic name, dupilumab, is a biologic medication. Approved by the FDA in 2017, Dupixent is used to treat eczema (atopic dermatitis), asthma, and six other chronic inflammatory conditions. It works by blocking signals of Type 2 inflammation, which the manufacturer says is an important component in how the body develops the conditions it treats.

The medication is in the form of a pre-filled injection pen that’s administered under the skin as a subcutaneous injection. Dosing and frequency of Dupixent depend on what it’s being used for.

Dupixent Side Effects

Like any medication, there are possible side effects of dupilumab. Oftentimes, certain groups of people have a greater risk of experiencing medication side effects.

The most common side effects of Dupixent are injection site reactions and eye problems, such as blurred vision, pink eye, and itchy or dry eyes. Cold sores, pain in the throat, high white blood cell count, insomnia, toothache, and stomach problems are less common side effects. It’s important to note that many adverse reactions to Dupixent are more prevalent with certain conditions.

The manufacturers also warn that Dupixent can cause serious side effects, including:

• Allergic reactions
• New or worsening eye pain and vision problems
• Vasculitis 
• Psoriasis
• Joint pain and aches 

Some of these side effects of dupilumab can require hospitalization; chest pain, shortness of breath, difficulty moving, and symptoms of an allergic reaction to a medication, like difficulty swallowing or breathing, are severe reactions that require immediate medical attention.

If you take Dupixet, review all side effects and warnings, and ask your doctor if you have any questions. Anyone who experiences new or worsening symptoms or health struggles while being treated with the medication should see their healthcare professional.

What is Cutaneous T-Cell Lymphoma?

Cutaneous T-cell lymphoma is a rare form of non-Hodgkin lymphoma that develops in the skin’s white blood cells (T-lymphocytes). It typically progresses slowly, but it’s chronic, meaning it isn’t curable. Early intervention is important.

Common symptoms of CTCL include patches of skin that are dry, red, and/or itchy, and appear scaly or bumpy. These symptoms are similar in appearance to eczema or psoriasis. Unfortunately, since these symptoms resemble a condition – eczema – that Dupixent treats, diagnosis can be delayed, allowing the cancer to progress. Diagnosing CTCL involves a biopsy of affected areas.

In its early stages, treatment of CTCL includes topical chemotherapy, steroid creams, and UV light therapy. Advanced progression of the disease requires more intense and targeted treatments, such as chemotherapy, immunotherapy, radiation, and bone marrow transplant. Clinical trials are crucial for patients in advanced stages and for those who didn’t respond to previous treatments.

Legal Options if You Develop CTCL After Taking Dupixent

We’re confident there’s strong evidence showing Dupixent manufacturers knew or should have known of the CTCL risk associated with their drug. Despite the research, Sanofi and Regeneron haven’t updated their dupilumab warning labels. Their failure to adequately warn consumers of the risks has caused people to suffer financial, physical, and emotional damage. A Dupixent lymphoma lawsuit can ensure you’re properly compensated and that the manufacturers are held accountable.

If you or a loved one were diagnosed with cutaneous T-cell lymphoma and used Dupixent, it’s important to speak with our dangerous drug attorneys to learn about your legal options. As the firm that filed Georgia’s first Dupixent lawsuit, we already have a deep understanding of cancer and treatments, and of research that will have a critical role in these cases.

Many factors affect these types of claims, all of which take time to organize for the best outcome and meet filing requirements. Test results and diagnosis information, treatments and medical costs, time off work, specialist appointments, and other documentation are the cornerstone to demonstrating the impact of CTCL – not just how it’s affected you and your family in the short-term, but how it will impact your future. And if a loved one died from the disease or complications related to the cancer, you may be eligible to file a wrongful death claim.

Childers, Schlueter & Smith can protect your rights, fight for justice on your behalf, and ease some of your burden so you can focus on your health. Contact us online or call 1-800-641-0098 for a free consultation.